The study was conducted on 50 anaemic end stage renal diseased (ESRD) patients who received erythropoietin therapy for correction of their anaemia. They were randomly selected from King Fahd nephrology unit, Kasr El-Eini hospital, Cairo University and from nephrology department, Arab Contractors Medical Center.They were classified according to their maximal haemoglobin (Hb) concentration achieved into two groups:•Group I: This included patients with subtotal Hb correction. •Group II: This included patients with full Hb correction. All patients were subjected to detailed history taking including, complete medical examination and investigations including initial and follow up CBC, iron studies and kidney functions. They were also monitored for the incidence of thromboembolic complications and comparing it with the improvement in quality of life parameters.The aim of our study is to compare the incidence of complications versus improvement in quality of life in patients with subtotal Hb concentration and those with total Hb correction in an attempt to clarify which target Hb concentration will be selected in the management of anemic ESRD patient.From this result we concluded that the more the increase in Hb level the more the improvement in quality of life, however, it is important that renal anaemic patients are considered as individuals and their treatment tailored according to their condition. It may be appropriate to attempt to normalize Hb concentration in some CRF patients, particularly if they are young, have an active lifestyle, and no severe co-morbidity. In contrast, partial correction would probably more appropriate for elderly patients with significant co-morbidities.